Research Article 
The epidemiology of Alzheimer‘s disease: Laying the foundation for drug design, conduct, and analysis of clinical trials
Kristine Yaffe, Michael Tocco, Ronald C. Petersen, Catherine Sigler, Leah C. Burns, Christel Cornelius, Ara S. Khachaturian, Michael C. Irizarry and Maria C. Carrillo
Alzheimer`s & Dementia, 2012, 8(3), 237-242. DOI: 10.1016/j.jalz.2011.12.005
Abstract
Epidemiological studies increasingly inform Alzheimer‘s disease (AD) public health impact, prevention strategies, drug targets, therapeutic interventions, and clinical trial design. For this reason, the Alzheimer‘s Association Research Roundtable convened an international group of AD experts with experience in conducting both observational and clinical trials for a meeting on October 19 and 20, 2010, in Washington, DC, to discuss the role of epidemiologic studies in AD research and therapeutic advances. Topics included wellness markers and risk factors, with a focus on special populations such as those at elevated risk, super agers, and underserved populations. Discussions also highlighted lessons learned from observational studies of aging, cardiovascular disease, and other disease areas, as well as how new technologies have enabled the gathering of data relevant to drug development and clinical trial conduct.
ASCI-ID: 285-196
Similar Articles
Fluorodeoxyglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 years
Alzheimer`s & Dementia, 2010, 6(4), 326-333. DOI: 10.1016/j.jalz.2009.09.005
Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” A national registry on agingAlzheimer`s & Dementia, 2009, 5(2), 105-107. DOI: 10.1016/j.jalz.2009.01.010
Dementia and Alzheimer‘s disease: A new direction. The 2010 Jay L. Foster Memorial LectureAlzheimer`s & Dementia, 2011, 7(5), 540-550. DOI: 10.1016/j.jalz.2011.05.901
A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in agingAlzheimer`s & Dementia, 2012, 8(5), 381-388. DOI: 10.1016/j.jalz.2011.10.005
Review of selected databases of longitudinal aging studiesAlzheimer`s & Dementia, 2012, 8(6), 584-589. DOI: 10.1016/j.jalz.2011.09.232
Alzheimer's disease pathology does not mediate the association between depressive symptoms and subsequent cognitive declineAlzheimer`s & Dementia, 2013, 9(3), 318-325. DOI: 10.1016/j.jalz.2011.11.009
A European perspective on population studies of dementiaAlzheimer`s & Dementia, 2011, 7(1), 3-9. DOI: 10.1016/j.jalz.2010.12.003
Operationalizing diagnostic criteria for Alzheimer‘s disease and other age-related cognitive impairment–Part 2Alzheimer`s & Dementia, 2011, 7(1), 35-52. DOI: 10.1016/j.jalz.2010.12.002
Sources of variability in estimates of the prevalence of Alzheimer‘s disease in the United StatesAlzheimer`s & Dementia, 2011, 7(1), 74-79. DOI: 10.1016/j.jalz.2010.11.006
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloidAlzheimer`s & Dementia, 2011, 7(2), 133-141. DOI: 10.1016/j.jalz.2010.08.230
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer`s & Dementia, 2011, 7(3), 257-262. DOI: 10.1016/j.jalz.2011.03.004
The Alzheimer‘s Association external quality control program for cerebrospinal fluid biomarkersAlzheimer`s & Dementia, 2011, 7(4), 386-395. DOI: 10.1016/j.jalz.2011.05.2243
Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer‘s disease study cohorts from phase 3 trials of semagacestat and solanezumabAlzheimer`s & Dementia, 2011, 7(4), 396-401. DOI: 10.1016/j.jalz.2011.05.2353
Extended results of the Alzheimer‘s disease anti-inflammatory prevention trialAlzheimer`s & Dementia, 2011, 7(4), 402-411. DOI: 10.1016/j.jalz.2010.12.014
Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer‘s diseaseAlzheimer`s & Dementia, 2011, 7(4), 425-435. DOI: 10.1016/j.jalz.2010.09.003
Intracranial atherosclerosis as a contributing factor to Alzheimer‘s disease dementiaAlzheimer`s & Dementia, 2011, 7(4), 436-444. DOI: 10.1016/j.jalz.2010.08.228
Transcranial Doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2011, 7(4), 445-455. DOI: 10.1016/j.jalz.2010.09.002
The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ɛ3/ɛ3 genotypeAlzheimer`s & Dementia, 2011, 7(4), 456-465. DOI: 10.1016/j.jalz.2010.11.012
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2011, 7(4), 474-485. DOI: 10.1016/j.jalz.2011.04.007
Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer‘s disease patientsAlzheimer`s & Dementia, 2011, 7(5), 493-500. DOI: 10.1016/j.jalz.2011.01.004
Frequency of Alzheimer‘s disease pathology at autopsy in patients with clinical normal pressure hydrocephalusAlzheimer`s & Dementia, 2011, 7(5), 509-513. DOI: 10.1016/j.jalz.2010.12.008
Long-term progression of Alzheimer‘s disease in patients under antidementia drugsAlzheimer`s & Dementia, 2011, 7(6), 579-592. DOI: 10.1016/j.jalz.2011.02.009
The measurement of everyday cognition: Development and validation of a short form of the Everyday Cognition scalesAlzheimer`s & Dementia, 2011, 7(6), 593-601. DOI: 10.1016/j.jalz.2011.02.007
Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer‘s disease trialsAlzheimer`s & Dementia, 2011, 7(6), 602-610. DOI: 10.1016/j.jalz.2011.01.005
An economic evaluation of early assessment for Alzheimer‘s disease in the United KingdomAlzheimer`s & Dementia, 2012, 8(1), 22-30. DOI: 10.1016/j.jalz.2010.07.001
Modeling Alzheimer‘s disease progression using the disease system analysis approachAlzheimer`s & Dementia, 2012, 8(1), 39-50. DOI: 10.1016/j.jalz.2010.12.012
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's diseaseAlzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization InitiativeAlzheimer`s & Dementia, 2012, 8(1), 65-73. DOI: 10.1016/j.jalz.2011.07.004
[123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodiesAlzheimer`s & Dementia, 2012, 8(1), 74-83. DOI: 10.1016/j.jalz.2011.08.003
An investigation of PreMCI: Subtypes and longitudinal outcomesAlzheimer`s & Dementia, 2012, 8(3), 172-179. DOI: 10.1016/j.jalz.2011.03.002
Serum antibodies to periodontal pathogens are a risk factor for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 196-203. DOI: 10.1016/j.jalz.2011.04.006
Cognitive and structural magnetic resonance imaging features of Lewy body dementia and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 211-218. DOI: 10.1016/j.jalz.2011.04.008
Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 219-226. DOI: 10.1016/j.jalz.2011.03.012
Alzheimer‘s disease: Pathogenesis and preventionAlzheimer`s & Dementia, 2012, 8(3), 227-233. DOI: 10.1016/j.jalz.2012.01.011
Safety and biomarker effects of solanezumab in patients with Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(4), 261-271. DOI: 10.1016/j.jalz.2011.09.224
Leptin and dementia over 32 years–The Prospective Population Study of WomenAlzheimer`s & Dementia, 2012, 8(4), 272-277. DOI: 10.1016/j.jalz.2011.05.2411
Gaining precision on the Alzheimer‘s Disease Assessment Scale-cognitive: A comparison of item response theory-based scores and total scoresAlzheimer`s & Dementia, 2012, 8(4), 288-294. DOI: 10.1016/j.jalz.2011.05.2409
Effect of human cerebrospinal fluid sampling frequency on amyloid-β levelsAlzheimer`s & Dementia, 2012, 8(4), 295-303. DOI: 10.1016/j.jalz.2011.05.900
Worldwide Alzheimer‘s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2012, 8(4), 337-342. DOI: 10.1016/j.jalz.2012.04.007
Some evolutionary perspectives on Alzheimer‘s disease pathogenesis and pathologyAlzheimer`s & Dementia, 2012, 8(4), 343-351. DOI: 10.1016/j.jalz.2011.05.2408
Cardiovascular fitness is associated with altered cortical glucose metabolism during working memory in ɛ4 carriersAlzheimer`s & Dementia, 2012, 8(4), 352-356. DOI: 10.1016/j.jalz.2011.04.010
Common Alzheimer‘s Disease Research Ontology: National Institute on Aging and Alzheimer‘s Association Collaborative ProjectAlzheimer`s & Dementia, 2012, 8(4), 372-375. DOI: 10.1016/j.jalz.2012.05.2115
A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in agingAlzheimer`s & Dementia, 2012, 8(5), 381-388. DOI: 10.1016/j.jalz.2011.10.005
Amyloid imaging in dementias with atypical presentationAlzheimer`s & Dementia, 2012, 8(5), 389-398. DOI: 10.1016/j.jalz.2011.07.003
Comparing new templates and atlas-based segmentations in the volumetric analysis of brain magnetic resonance images for diagnosing Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(5), 399-406. DOI: 10.1016/j.jalz.2011.07.002
Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studiesAlzheimer`s & Dementia, 2012, 8(5), 407-416. DOI: 10.1016/j.jalz.2011.05.2413
Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound BAlzheimer`s & Dementia, 2012, 8(6), 496-501. DOI: mailto:[email protected]
Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smokingAlzheimer`s & Dementia, 2012, 8(6), 513-519. DOI: 10.1016/j.jalz.2011.10.006
Differential prediction of vascular dementia and Alzheimer‘s disease in nondemented older adults within 5 years of initial testingAlzheimer`s & Dementia, 2012, 8(6), 528-535. DOI: 10.1016/j.jalz.2011.09.233
A new informant-based questionnaire for instrumental activities of daily living in dementiaAlzheimer`s & Dementia, 2012, 8(6), 536-543. DOI: 10.1016/j.jalz.2011.08.006
Comparison of International Working Group criteria and National Institute on Aging–Alzheimer‘s Association criteria for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(6), 560-563. DOI: 10.1016/j.jalz.2011.10.008
Association of environmental tobacco smoke with dementia and Alzheimer‘s disease among never smokersAlzheimer`s & Dementia, 2012, 8(6), 590-595. DOI: 10.1016/j.jalz.2011.09.231
The worldwide economic impact of dementia 2010Alzheimer`s & Dementia, 2013, 9(1), 1-11. DOI: 10.1016/j.jalz.2012.11.006
Apolipoprotein E genotype, dementia, and mortality in the oldest old: The 90+ StudyAlzheimer`s & Dementia, 2013, 9(1), 12-18. DOI: 10.1016/j.jalz.2011.12.004
Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer‘s disease and related disordersAlzheimer`s & Dementia, 2013, 9(1), 30-38. DOI: 10.1016/j.jalz.2012.11.002
The economics of mild cognitive impairmentAlzheimer`s & Dementia, 2013, 9(1), 58-62. DOI: 10.1016/j.jalz.2012.05.2117
Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on AgingAlzheimer`s & Dementia, 2013, 9(2), 113-122. DOI: 10.1016/j.jalz.2011.09.223
Intracerebral propagation of Alzheimer‘s disease: Strengthening evidence of a herpes simplex virus etiologyAlzheimer`s & Dementia, 2013, 9(2), 169-175. DOI: 10.1016/j.jalz.2012.07.005
Phenotypic regional functional imaging patterns during memory encoding in mild cognitive impairment and Alzheimer's diseaseAlzheimer`s & Dementia, 2013, 9(3), 284-294. DOI: 10.1016/j.jalz.2011.12.006
Effectiveness of antidementia drugs in delaying Alzheimer's disease progressionAlzheimer`s & Dementia, 2013, 9(3), 338-345. DOI: 10.1016/j.jalz.2012.01.002
Risk disclosure and preclinical Alzheimer‘s disease clinical trial enrollmentAlzheimer`s & Dementia, 2013, 9(3), 356-359. DOI: 10.1016/j.jalz.2012.03.001
β-Site amyloid precursor protein–cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tauAlzheimer`s & Dementia, 2013, 9(4), 386-391. DOI: 10.1016/j.jalz.2012.01.015
Physician outpatient contacts and hospitalizations among cognitively impaired elderlyAlzheimer`s & Dementia, 2009, 5(1), 30-42. DOI: 10.1016/j.jalz.2008.05.2493
Dementia literacy: Recognition and beliefs on dementia of the Australian publicAlzheimer`s & Dementia, 2009, 5(1), 43-49. DOI: 10.1016/j.jalz.2008.03.011
Associations among measures of awareness of cognitive deficits in dementiaAlzheimer`s & Dementia, 2010, 6(4), 312-318. DOI: 10.1016/j.jalz.2009.06.005
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008Alzheimer`s & Dementia, 2009, 5(2), 85-92. DOI: 10.1016/j.jalz.2009.01.021
Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” A national registry on agingAlzheimer`s & Dementia, 2009, 5(2), 105-107. DOI: 10.1016/j.jalz.2009.01.010
Commentary on `A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.` Establishing a national biomarker database: Utility and incentivesAlzheimer`s & Dementia, 2009, 5(2), 108-113. DOI: 10.1016/j.jalz.2009.01.015
Commentary on `A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.` Facilitating Alzheimer's disease drug development in the United StatesAlzheimer`s & Dementia, 2009, 5(2), 125-127. DOI: 10.1016/j.jalz.2009.01.005
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” A national registry to identify a cohort for Alzheimer's disease prevention studiesAlzheimer`s & Dementia, 2009, 5(2), 128-129. DOI: 10.1016/j.jalz.2009.01.018
Commentary on `A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.` Alzheimer's disease translational research programs at the National Institute on AgingAlzheimer`s & Dementia, 2009, 5(2), 130-132.
Commentary on ”map for the prevention of dementia II: Leon Thal Symposium 2008.” ”Big Asks”: What can be changed to increase and speed progress on Alzheimer's disease research and treatment?Alzheimer`s & Dementia, 2009, 5(2), 137-139. DOI: 10.1016/j.jalz.2009.01.003
Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ A proposal to increase participation in Alzheimer's disease clinical trialsAlzheimer`s & Dementia, 2009, 5(2), 140-142. DOI: 10.1016/j.jalz.2009.01.004
Commentary on ”A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.“ Rationale and recommendations for first evaluating anti-Alzheimer's disease medications in acute brain injury patientsAlzheimer`s & Dementia, 2009, 5(2), 143-146. DOI: 10.1016/j.jalz.2009.01.013
Commentary on ”A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.“ Who may benefit from disease-modifying studies in Alzheimer's disease?Alzheimer`s & Dementia, 2009, 5(2), 147-148. DOI: 10.1016/j.jalz.2009.01.007
Commentary on ”A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.“ Primary prevention of dementia in Alzheimer's disease: A perspective from prevention research in cardiovascular disease and strokeAlzheimer`s & Dementia, 2009, 5(2), 149-153. DOI: 10.1016/j.jalz.2009.01.012
Commentary on ”A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.“ Primary prevention of dementia in Alzheimer's disease: A perspective from prevention research in cardiovascular disease and strokeAlzheimer`s & Dementia, 2009, 5(2), 149-153. DOI: 10.1016/j.jalz.2009.01.012
Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ Subjective cognitive impairment as an antecedent of Alzheimer's dementia: Policy importAlzheimer`s & Dementia, 2009, 5(2), 154-156. DOI: 10.1016/j.jalz.2009.01.011
Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ Subjective cognitive impairment as an antecedent of Alzheimer's dementia: Policy importAlzheimer`s & Dementia, 2009, 5(2), 154-156. DOI: 10.1016/j.jalz.2009.01.011
Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ Comments from abroadAlzheimer`s & Dementia, 2009, 5(2), 157-158. DOI: 10.1016/j.jalz.2009.01.009
Commentary on ” A roadmap for the prevention of dementia II: Leon Thal symposium 2008.“ The megacommunity approach to Alzheimer's diseaseAlzheimer`s & Dementia, 2009, 5(2), 163-165. DOI: 10.1016/j.jalz.2009.02.002
Commentary on ” A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“ Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: Opportunities and challengesAlzheimer`s & Dementia, 2009, 5(2), 166-171. DOI: 10.1016/j.jalz.2008.12.002
Commentary on ”A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.“A federally funded corporation for the prevention and treatment of cognitive impairment and brain agingAlzheimer`s & Dementia, 2009, 5(2), 172-179. DOI: 10.1016/j.jalz.2009.01.023
Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-oldAlzheimer`s & Dementia, 2009, 5(4), 318-323. DOI: 10.1016/j.jalz.2009.04.1230
Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whitesAlzheimer`s & Dementia, 2009, 5(6), 445-453. DOI: 10.1016/j.jalz.2009.04.1234
Closing the dementia care gap: Can referral to Alzheimer's Association chapters help?Alzheimer`s & Dementia, 2009, 5(6), 498-502. DOI: 10.1016/j.jalz.2009.01.024
Outcome over seven years of healthy adults with and without subjective cognitive impairmentAlzheimer`s & Dementia, 2010, 6(1), 11-24. DOI: 10.1016/j.jalz.2009.10.002
White matter integrity and cortical metabolic associations in aging and dementiaAlzheimer`s & Dementia, 2010, 6(1), 54-62. DOI: 10.1016/j.jalz.2009.04.1228
Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysisAlzheimer`s & Dementia, 2010, 6(1), 70-74. DOI: 10.1016/j.jalz.2009.04.1231
Early dementia diagnosis and the risk of suicide and euthanasiaAlzheimer`s & Dementia, 2010, 6(1), 75-82. DOI: 10.1016/j.jalz.2009.04.1229
The worldwide societal costs of dementia: Estimates for 2009Alzheimer`s & Dementia, 2010, 6(2), 98-103. DOI: 10.1016/j.jalz.2010.01.010
A European perspective on population studies of dementiaAlzheimer`s & Dementia, 2011, 7(1), 3-9. DOI: 10.1016/j.jalz.2010.12.003
Counting dementia: There is no one ”best“ wayAlzheimer`s & Dementia, 2011, 7(1), 10-14. DOI: 10.1016/j.jalz.2010.11.003
Operationalizing diagnostic criteria for Alzheimer‘s disease and other age-related cognitive impairment–Part 2Alzheimer`s & Dementia, 2011, 7(1), 35-52. DOI: 10.1016/j.jalz.2010.12.002
Sources of variability in estimates of the prevalence of Alzheimer‘s disease in the United StatesAlzheimer`s & Dementia, 2011, 7(1), 74-79. DOI: 10.1016/j.jalz.2010.11.006
Serum homocysteine and dementia: Meta-analysis of eight cohort studies including 8669 participantsAlzheimer`s & Dementia, 2011, 7(4), 412-417. DOI: 10.1016/j.jalz.2010.08.234
How golden is the gold standard of neuropathology in dementia?Alzheimer`s & Dementia, 2011, 7(4), 486-489. DOI: 10.1016/j.jalz.2011.04.011
Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer‘s disease patientsAlzheimer`s & Dementia, 2011, 7(5), 493-500. DOI: 10.1016/j.jalz.2011.01.004
Frequency of Alzheimer‘s disease pathology at autopsy in patients with clinical normal pressure hydrocephalusAlzheimer`s & Dementia, 2011, 7(5), 509-513. DOI: 10.1016/j.jalz.2010.12.008
Dementia and Alzheimer‘s disease: A new direction. The 2010 Jay L. Foster Memorial LectureAlzheimer`s & Dementia, 2011, 7(5), 540-550. DOI: 10.1016/j.jalz.2011.05.901
Videoconference diagnosis and management of Choctaw Indian dementia patientsAlzheimer`s & Dementia, 2011, 7(6), 562-566. DOI: 10.1016/j.jalz.2011.02.006
Predictors of suicide in patients with dementiaAlzheimer`s & Dementia, 2011, 7(6), 567-573. DOI: 10.1016/j.jalz.2011.01.006
Functional deficits among patients with mild cognitive impairmentAlzheimer`s & Dementia, 2011, 7(6), 611-614. DOI: 10.1016/j.jalz.2010.12.011
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's diseaseAlzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003
Psychosocial stress at work is associated with increased dementia risk in late lifeAlzheimer`s & Dementia, 2012, 8(2), 114-120. DOI: 10.1016/j.jalz.2011.03.001
Some evolutionary perspectives on Alzheimer‘s disease pathogenesis and pathologyAlzheimer`s & Dementia, 2012, 8(4), 343-351. DOI: 10.1016/j.jalz.2011.05.2408
Analysis of case management programs for patients with dementia: A systematic reviewAlzheimer`s & Dementia, 2012, 8(5), 426-436. DOI: 10.1016/j.jalz.2011.06.004
Antihypertensive drug use and the risk of dementia in patients with diabetes mellitusAlzheimer`s & Dementia, 2012, 8(5), 437-444. DOI: 10.1016/j.jalz.2011.05.2414
Impact of the Food and Drug Administration‘s antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settingsAlzheimer`s & Dementia, 2012, 8(5), 453-457. DOI: 10.1016/j.jalz.2011.08.004
Predictive validity and diagnostic stability of mild cognitive impairment subtypesAlzheimer`s & Dementia, 2012, 8(6), 553-559.
Association of environmental tobacco smoke with dementia and Alzheimer‘s disease among never smokersAlzheimer`s & Dementia, 2012, 8(6), 590-595. DOI: 10.1016/j.jalz.2011.09.231
The worldwide economic impact of dementia 2010Alzheimer`s & Dementia, 2013, 9(1), 1-11. DOI: 10.1016/j.jalz.2012.11.006
Apolipoprotein E genotype, dementia, and mortality in the oldest old: The 90+ StudyAlzheimer`s & Dementia, 2013, 9(1), 12-18. DOI: 10.1016/j.jalz.2011.12.004
Dementia and out-of-pocket spending on health care servicesAlzheimer`s & Dementia, 2013, 9(1), 19-29. DOI: 10.1016/j.jalz.2011.11.003
The global prevalence of dementia: A systematic review and metaanalysisAlzheimer`s & Dementia, 2013, 9(1), 63-75. DOI: 10.1016/j.jalz.2012.11.007
Vascular disease and dementias: Paradigm shifts to drive research in new directionsAlzheimer`s & Dementia, 2013, 9(1), 76-92. DOI: 10.1016/j.jalz.2012.02.007
Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on AgingAlzheimer`s & Dementia, 2013, 9(2), 113-122. DOI: 10.1016/j.jalz.2011.09.223
Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care settingAlzheimer`s & Dementia, 2013, 9(2), 141-150. DOI: 10.1016/j.jalz.2012.09.011
Improving dementia care: The role of screening and detection of cognitive impairmentAlzheimer`s & Dementia, 2013, 9(2), 151-159. DOI: 10.1016/j.jalz.2012.08.008
A prediction model to calculate probability of Alzheimer‘s disease using cerebrospinal fluid biomarkersAlzheimer`s & Dementia, 2013, 9(3), 262-268. DOI: 10.1016/j.jalz.2012.01.010
Mild cognitive impairment in a community sample: The Sydney Memory and Ageing StudyAlzheimer`s & Dementia, 2013, 9(3), 310-317. DOI: 10.1016/j.jalz.2011.11.010
Prevalence of mild cognitive impairment subtypes in patients attending a memory outpatient clinic—comparison of two modes of mild cognitive impairment classification. Results of the Vienna Conversion to Dementia StudyAlzheimer`s & Dementia, 2013, 9(4), 366-376. DOI: 10.1016/j.jalz.2011.12.009
Long–term anticholinergic use and the aging brainAlzheimer`s & Dementia, 2013, 9(4), 377-385. DOI: 10.1016/j.jalz.2012.02.005
β-Site amyloid precursor protein–cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tauAlzheimer`s & Dementia, 2013, 9(4), 386-391. DOI: 10.1016/j.jalz.2012.01.015
Risk of Alzheimer's disease incidence attributable to vascular disease in the populationAlzheimer`s & Dementia, 2011, 7(3), 356-360. DOI: 10.1016/j.jalz.2010.12.004
Dementia and Alzheimer‘s disease: A new direction. The 2010 Jay L. Foster Memorial LectureAlzheimer`s & Dementia, 2011, 7(5), 540-550. DOI: 10.1016/j.jalz.2011.05.901
Mild cognitive impairment: Disparity of incidence and prevalence estimatesAlzheimer`s & Dementia, 2012, 8(1), 14-21. DOI: 10.1016/j.jalz.2011.01.002
Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studiesAlzheimer`s & Dementia, 2012, 8(5), 407-416. DOI: 10.1016/j.jalz.2011.05.2413
Vascular risk factors, apolipoprotein E, and hippocampal decline on magnetic resonance imaging over a 10-year follow-upAlzheimer`s & Dementia, 2012, 8(5), 417-425. DOI: 10.1016/j.jalz.2011.07.005
No association between gain in body mass index across the life course and midlife cognitive function and cognitive reserve–The 1946 British birth cohort studyAlzheimer`s & Dementia, 2012, 8(6), 470-482. DOI: 10.1016/j.jalz.2011.09.228
The global prevalence of dementia: A systematic review and metaanalysisAlzheimer`s & Dementia, 2013, 9(1), 63-75. DOI: 10.1016/j.jalz.2012.11.007
The basis for disease-modifying treatments for Alzheimer`s disease: The Sixth Annual Mild Cognitive Impairment SymposiumAlzheimer`s & Dementia, 2009, 5(1), 66-74. DOI: 10.1016/j.jalz.2008.10.006
Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trialsAlzheimer`s & Dementia, 2010, 6(5), 367-377. DOI: 10.1016/j.jalz.2010.07.004
Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume lossAlzheimer`s & Dementia, 2010, 6(5), 378-385. DOI: 10.1016/j.jalz.2010.03.014
Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjectsAlzheimer`s & Dementia, 2010, 6(3), 230-238. DOI: 10.1016/j.jalz.2010.03.008
The Alzheimer’s Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomesAlzheimer`s & Dementia, 2010, 6(3), 257-264. DOI: 10.1016/j.jalz.2010.03.002
Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer’s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2010, 6(3), 291-296. DOI: 10.1016/j.jalz.2010.03.009
Atypical event-related potentials in patients with mild cognitive impairment: An identification-priming studyAlzheimer`s & Dementia, 2010, 6(4), 351-358. DOI: 10.1016/j.jalz.2009.05.664
Association of C-reactive protein with mild cognitive impairmentAlzheimer`s & Dementia, 2009, 5(5), 398-405. DOI: 10.1016/j.jalz.2009.01.025
Outcome over seven years of healthy adults with and without subjective cognitive impairmentAlzheimer`s & Dementia, 2010, 6(1), 11-24. DOI: 10.1016/j.jalz.2009.10.002
A European perspective on population studies of dementiaAlzheimer`s & Dementia, 2011, 7(1), 3-9. DOI: 10.1016/j.jalz.2010.12.003
Operationalizing diagnostic criteria for Alzheimer‘s disease and other age-related cognitive impairment–Part 2Alzheimer`s & Dementia, 2011, 7(1), 35-52. DOI: 10.1016/j.jalz.2010.12.002
Sources of variability in estimates of the prevalence of Alzheimer‘s disease in the United StatesAlzheimer`s & Dementia, 2011, 7(1), 74-79. DOI: 10.1016/j.jalz.2010.11.006
The diagnosis of mild cognitive impairment due to Alzheimer‘s disease: Recommendations from the National Institute on Aging-Alzheimer‘s Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer`s & Dementia, 2011, 7(3), 270-279. DOI: 10.1016/j.jalz.2011.03.008
The measurement of everyday cognition: Development and validation of a short form of the Everyday Cognition scalesAlzheimer`s & Dementia, 2011, 7(6), 593-601. DOI: 10.1016/j.jalz.2011.02.007
Functional deficits among patients with mild cognitive impairmentAlzheimer`s & Dementia, 2011, 7(6), 611-614. DOI: 10.1016/j.jalz.2010.12.011
Mild cognitive impairment: Disparity of incidence and prevalence estimatesAlzheimer`s & Dementia, 2012, 8(1), 14-21. DOI: 10.1016/j.jalz.2011.01.002
Cognitive impairment in nondemented oldest-old: Prevalence and relationship to cardiovascular risk factorsAlzheimer`s & Dementia, 2012, 8(2), 87-94. DOI: 10.1016/j.jalz.2011.02.008
Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(2), 105-113. DOI: 10.1016/j.jalz.2011.05.2416
An investigation of PreMCI: Subtypes and longitudinal outcomesAlzheimer`s & Dementia, 2012, 8(3), 172-179. DOI: 10.1016/j.jalz.2011.03.002
Serum antibodies to periodontal pathogens are a risk factor for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 196-203. DOI: 10.1016/j.jalz.2011.04.006
Comparing new templates and atlas-based segmentations in the volumetric analysis of brain magnetic resonance images for diagnosing Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(5), 399-406. DOI: 10.1016/j.jalz.2011.07.002
A new informant-based questionnaire for instrumental activities of daily living in dementiaAlzheimer`s & Dementia, 2012, 8(6), 536-543. DOI: 10.1016/j.jalz.2011.08.006
Computer-related self-efficacy and anxiety in older adults with and without mild cognitive impairmentAlzheimer`s & Dementia, 2012, 8(6), 544-552. DOI: 10.1016/j.jalz.2011.12.008
The economics of mild cognitive impairmentAlzheimer`s & Dementia, 2013, 9(1), 58-62. DOI: 10.1016/j.jalz.2012.05.2117
Phenotypic regional functional imaging patterns during memory encoding in mild cognitive impairment and Alzheimer's diseaseAlzheimer`s & Dementia, 2013, 9(3), 284-294. DOI: 10.1016/j.jalz.2011.12.006
Mild cognitive impairment in a community sample: The Sydney Memory and Ageing StudyAlzheimer`s & Dementia, 2013, 9(3), 310-317. DOI: 10.1016/j.jalz.2011.11.010
Predictors and outcomes for caregivers of people with mild cognitive impairment: A systematic literature reviewAlzheimer`s & Dementia, 2013, 9(3), 346-355. DOI: 10.1016/j.jalz.2012.01.012
Long–term anticholinergic use and the aging brainAlzheimer`s & Dementia, 2013, 9(4), 377-385. DOI: 10.1016/j.jalz.2012.02.005